ESSA Pharma Inc.
EPIXDelisted Oct 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001633932
ESSA Pharma Inc. was delisted on Oct 9, 2025; its insiders filed their last Form 4 on Oct 15, 2025; 32 institutions reported holding it in 13F filings for Q3 2025, worth $4.30M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by ESSA Pharma Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for ESSA Pharma Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Berger Franklin M | Director | 0 | Oct 15, 2025 | 1 |
| Glickman Richard M | Director | 0 | Oct 15, 2025 | 1 |
| Parkinson David Ross | President and CEO | 0 | Oct 15, 2025 | 1 |
| Martin John Alexander | Director | 0 | Oct 15, 2025 | 1 |
| Requadt Scott | Director | 0 | Oct 15, 2025 | 1 |
| Thorell Marella | Director | 0 | Oct 15, 2025 | 1 |
| Wood David S. | Chief Financial Officer | 0 | Oct 15, 2025 | 1 |
| Biotechnology Value Fund L P | 10% Owner | 0 | Oct 14, 2025 | 1 |
| BVF Partners L P | 10% Owner | 0 | Oct 14, 2025 | 1 |
| BVF Inc | 10% Owner | 0 | Oct 14, 2025 | 1 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 0 | Oct 14, 2025 | 1 |
| Lampert Mark N | 10% Owner | 0 | Oct 14, 2025 | 1 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 0 | Oct 14, 2025 | 1 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 0 | Oct 14, 2025 | 1 |
| BVF I GP LLC | 10% Owner | 0 | Oct 14, 2025 | 1 |
| BVF II GP LLC | Other: See Explanation of Responses | 0 | Oct 14, 2025 | 1 |
| BVF GP Holdings LLC | 10% Owner | 0 | Oct 14, 2025 | 1 |
| BB Biotech AG | 10% Owner | 0 | Nov 5, 2024 | 0 |
| Biotech Growth N V | 10% Owner | 0 | Nov 5, 2024 | 0 |
| Virsik Peter | Chief Operating Officer | 7,776 | Oct 7, 2024 | 0 |
| Zweifach Sanford S | Director | – | Mar 28, 2024 | 0 |
| Sollis Gary | Director | – | Mar 28, 2024 | 0 |
| Cesano Alessandra | Chief Medical Officer | – | Mar 28, 2024 | 0 |
| Merendino Lauren | Director | – | Mar 28, 2024 | 0 |
| Kantoff Philip W. | Director | – | Mar 28, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2025 (view filing)4:36 PM ET | Aug 5 | 2 days | Biotechnology Value Fund L P and 9 others10% Owner | SSale | −156 | $1.88 | −$292.95 | 0.0%560.8K after | 3 lots |
| Nov 5, 2024 (view filing)12:06 PM ET | Nov 1 | 4 days | BB Biotech AG and 1 other10% Owner | SSale | −7.88M | $1.53 | −$12.0M | −100.0%0 after | 4 lots |
| Oct 7, 2024 (view filing) | Oct 7 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $6.03 | −$4.18K | −8.2%7.78K after | 10b5-1 |
| Sep 9, 2024 (view filing) | Sep 9 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $6.00 | −$4.16K | −7.6%8.47K after | 10b5-1 |
| Sep 3, 2024 (view filing) | Sep 3 | Same day | Virsik PeterChief Operating Officer | SSale | −2.08K | $6.03 | −$12.6K | −18.5%9.16K after | 10b5-1 |
| May 6, 2024 (view filing) | May 6 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $6.95 | −$4.82K | −5.8%11.2K after | 10b5-1 |
| Apr 5, 2024 (view filing) | Apr 5 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $7.94 | −$5.51K | −5.5%11.9K after | 10b5-1 |
| Mar 5, 2024 (view filing) | Mar 5 | Same day | Virsik PeterChief Operating Officer | SSale | −694 | $8.98 | −$6.23K | −5.2%12.6K after | 10b5-1 |
| Feb 7, 2024 (view filing) | Feb 6 | 1 day | Virsik PeterChief Operating Officer | SSale | −72.8K | $10.29 | −$748.9K | −84.5%13.3K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Virsik PeterChief Operating Officer | SSale | −1.19K | $9.58 | −$11.4K | −8.2%13.3K after | 2 lots10b5-1 |
| Jan 17, 2024 (view filing) | Jan 16 | 1 day | Virsik PeterChief Operating Officer | SSale | −1.72K | $10.01 | −$17.2K | −10.9%14.0K after | 10b5-1 |
| Jan 8, 2024 (view filing) | Jan 5 | 3 days | Virsik PeterChief Operating Officer | SSale | −699 | $6.11 | −$4.27K | −4.7%14.0K after | 10b5-1 |
| Dec 18, 2023 (view filing) | Dec 14 | 4 days | Parkinson David RossChief Executive Officer | PPurchase | +9.22K | $2.30 | +$21.2K | +16.3%65.7K after | |
| Nov 22, 2023 (view filing) | Nov 21 | 1 day | Berger Franklin MDirector | PPurchase | +23.3K | $5.73 | +$133.3K | +3.1%784.4K after | |
| Nov 16, 2023 (view filing) | Nov 2-3 | 14 daysLate | Berger Franklin MDirector | PPurchase | +76.5K | $5.49 | +$419.7K | +11.2%760.9K after | 2 lots |
| Jan 5, 2023 (view filing) | Dec 22-30, 2022 | 14 daysLate | Parkinson David RossChief Executive Officer | PPurchase | +24.4K | $2.42 | +$59.0K | +76.1%56.5K after | 2 lots |
| Jan 5, 2023 (view filing) | Dec 14-21, 2022 | 22 daysLate | Berger Franklin MDirector | SSale | −272.8K | $2.67 | −$729.1K | −28.5%684.4K after | 7 lots |
| Jan 5, 2023 (view filing) | Dec 30, 2022 | 6 daysLate | Wood David S.Chief Financial Officer | PPurchase | +8.30K | $2.60 | +$21.6K | +33.2%33.3K after | |
| Oct 28, 2022 (view filing)2:57 PM ET | Oct 26-27 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +2.00M | $4.11 | +$8.22M | +34.0%7.88M after | 2 lots |
| Jul 20, 2022 (view filing)3:21 PM ET | Jul 18 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +300.0K | $3.16 | +$946.7K | +5.4%5.88M after | |
| Jul 18, 2022 (view filing)12:48 PM ET | Jul 14-15 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +588.9K | $2.93 | +$1.73M | +11.8%5.58M after | 2 lots |
| Jul 5, 2022 (view filing) | Jun 30 | 5 days | Parkinson David RossChief Executive Officer | PPurchase | +4.89K | $2.96 | +$14.5K | +18.0%32.1K after | |
| Apr 28, 2022 (view filing)12:28 PM ET | Apr 27 | 1 day | BB Biotech AG and 1 other10% Owner | SSale | −25.1K | $5.85 | −$146.9K | −0.5%4.99M after | |
| Aug 20, 2021 (view filing)12:43 PM ET | Aug 18 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +250.0K | $8.88 | +$2.22M | +5.2%5.02M after |